3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia
2
Tuberous Sclerosis
1
Tourette Syndrome
1
Tic Disorders
1
Preleukemia
1
Neurodevelopmental Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Hematologic Diseases
1
Glioblastoma
1
Fragile X Syndrome
1
DiGeorge Syndrome
1
Depression
1
Cytopenia
1
Bone Marrow Diseases
1
Autistic Disorder
1
Autism Spectrum Disorder
1
Attention Deficit Disorder with Hyperactivity
1
Anxiety Disorders
1
Anemia
1
22q11 Deletion Syndrome
1
Interventions
Cyclophosphamide
20
Brentuximab Vedotin
20
fludarabine
16
Lenalidomide
13
Rituximab
12
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
pirtobrutinib
6
Doxorubicin
6
Bortezomib
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
venetoclax
3
nilotinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Diseases
×
Sertraline
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled